The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2018 | Primary CNS lymphoma: can we use MATRix immunochemo in the real world?
MATRix immunochemotherapy induction therapy has produced promising results in the recent IELSG 32 trial (NCT01011920) for primary CNS lymphoma (PCNSL). However, here at the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Christopher Fox, MBChB(Hons), MRCP, FRCPath, of Nottingham University Hospitals NHS Trust, Nottingham, UK, raises the question of whether this data can be replicated in real world settings, particularly in difficult patient groups. Dr Fox highlights how recent data using MATRix for PCNSL in the real world has produced good results, suggesting that there is hope for MATRix therapy.
